Dynamic Neuromuscular Stabilization Training in Dysfunctional Voiding

September 13, 2023 updated by: Duygu Şahin Altaç, Halic University

The Effect of Dynamic Neuromuscular Stabilization Training in Dysfunctional Voiding : A Randomized Clinical Trial

In this study, the effect of dynamic neuromuscular stabilization (DNS) exercise on urinary flow and quality of life in individuals with dysfunctional voiding was investigated. The 34 participants included in the study were randomized into two groups: the experiment in which DNS exercises were applied and the standard therapy group in which the manual application was applied. Uroflowmetry, Voiding Symptom Score (DVSS), Short Form-36 Quality of Life Assessment Short Form were applied to all participants at baseline and at week 6.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

In this study, the effect of dynamic neuromuscular stabilization (DNS) exercise on urinary flow and quality of life in individuals with dysfunctional voiding was investigated. This experimental study was conducted with patients who applied to UroKlinik in Istanbul between March 2021 and June 2023 and were diagnosed with dysfunctional voiding. The 34 participants included in the study were randomized into two groups: the experiment in which DNS exercises were applied and the standard therapy group in which the manual application was applied. Voiding Symptom Score (DVSS), Short Form-36 Quality of Life Assessment Short Form and Uroflowmetry test were applied to all participants before and at week 6.

Study Type

Interventional

Enrollment (Actual)

34

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Turkey
      • Istanbul, Turkey
        • Haliç University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Having been diagnosed with dysfunctional voiding,
  • Being between the ages of 18-75,
  • Not having a neurogenic bladder
  • Not having a urinary tract infection
  • Not having an obstacle to exercise,
  • Accepting and signing the Approval Form,
  • Not having undergone surgery in the last 6 months,

Exclusion Criteria:

  • Not being cooperative
  • Not being able to participate in the treatment,
  • The use of drugs that will affect urination

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Other
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Dynamic Neuromuscular Stabilisation Exercise
The participants performed DNS exercises addition to standard therapy
Other: Exercise
Dynamic Neuromuscular Stabilisation Exercise
Other: Standard therapy
Patient education, massage, diaphragmatic breathing, kegel exercise
Other: Standard therapy
Patient education, massage, diaphragmatic breathing, kegel exercise
Other: Standard therapy
Patient education, massage, diaphragmatic breathing, kegel exercise

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Uroflowmetry - Maximum flow rate (Qmax)
Time Frame: at the baseline and at week 6.

Uroflowmetry gives information about urine flow rate and voiding pattern.

*Qmax (mL/s): Qmax is the fastest stream measured in mL/s.
at the baseline and at week 6.
Uroflowmetry - Average flow rate (Qave)
Time Frame: at the baseline and at week 6.

Uroflowmetry gives information about urine flow rate and voiding pattern.

*Qave (mL/s): Qave is the average stream measured in mL/s.
at the baseline and at week 6.
Uroflowmetry - Corrected maximum flow rate (cQmax)
Time Frame: at the baseline and at week 6.

Uroflowmetry gives information about urine flow rate and voiding pattern.

*cQmax (mL/s/√ mL): cQmax is the precise assessment of fastest stream, especially at high volumes. Is it estimated Qmax/√ VV.
at the baseline and at week 6.
Uroflowmetry - Flow time (FT)
Time Frame: at the baseline and at week 6.

Uroflowmetry gives information about urine flow rate and voiding pattern.

*FT (s): FT is the time over which measurable flow actually occurs.
at the baseline and at week 6.
Uroflowmetry - Voiding volume (VV)
Time Frame: at the baseline and at week 6.

Uroflowmetry gives information about urine flow rate and voiding pattern.

*VV (ml): VV indicates the amount of voiding.
at the baseline and at week 6.
Uroflowmetry - Residual urine (RU)
Time Frame: at the baseline and at week 6.

Uroflowmetry gives information about urine flow rate and voiding pattern.

*RU (ml): RU is the amount of urine that is left behind in the bladder after you are done urinating.
at the baseline and at week 6.
Dysfunctional Voiding and Incontinence Symptom Score
Time Frame: at the baseline and at week 6.
It gives information about voiding and incontinence symptoms. The questionnaire contains fourteen questions about symptoms and quality of life. The total score ranges from 0 to 35 and a score above 8.5 indicates abnormalities.
at the baseline and at week 6.
Short Form 36
Time Frame: at the baseline and at week 6.
It gives information about health related quality of life. The total score of the scale ranges from 0 to 100, and a high score indicates a high quality of life.
at the baseline and at week 6.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Halic University

Investigators

  • Study Director: Seda Saka, PhD, Haliç University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

March 2, 2021

Primary Completion (Actual)

April 7, 2023

Study Completion (Actual)

June 21, 2023

Study Registration Dates

First Submitted

August 29, 2023

First Submitted That Met QC Criteria

September 13, 2023

First Posted (Actual)

September 15, 2023

Study Record Updates

Last Update Posted (Actual)

September 15, 2023

Last Update Submitted That Met QC Criteria

September 13, 2023

Last Verified

September 1, 2023

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • ssaka8

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Dysfunctional Voiding

Clinical Trials on Exercise

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Portugal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe